SAMH
NTLA icon

Shanda Asset Management Holdings’s Intellia Therapeutics NTLA Stock Holding History

Shanda Asset Management Holdings’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-48,657
Closed -$797K – 37
2019
Q2 		$797K Hold
48,657
– – 0.15% 21
2019
Q1 		$831K Hold
48,657
– – 0.13% 39
2018
Q4 		$664K Buy
+48,657
New +$904K 0.12% 38

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Shanda Asset Management Holdings's NTLA Position: Q3 2019 in Review

Shanda Asset Management Holdings sold out of Intellia Therapeutics (NTLA) in Q3 2019, closing a stake of 48,657 shares — an estimated $797K sold.

Shanda Asset Management Holdings first reported a position in NTLA in Q4 2018 and held it in 3 quarters. The position peaked at $831K in Q1 2019. 136 funds tracked by Wall St. Rank hold NTLA as of Q3 2019.

  • Shanda Asset Management Holdings reported no remaining Intellia Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Shanda Asset Management Holdings sold 48,657 Intellia Therapeutics shares in Q3 2019, an estimated $797K.
  • Shanda Asset Management Holdings first reported a position in Intellia Therapeutics in Q4 2018 and held it in 3 quarters.
  • Shanda Asset Management Holdings's Intellia Therapeutics position peaked at $831K in Q1 2019.
  • 136 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2019.

Based on Shanda Asset Management Holdings's 13F filing for Q3 2019, filed 14 Nov 2019.